close

Enter

Log in using OpenID

Peptide Receptor Radionuclide Therapy (PRRT) Market showing Compound annual growth rate and forecast till 2026

embed
Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy a peptide similar to the natural hormone is combined with radioactive ma
Peptide Receptor Radionuclide Therapy (PRRT)
Market showing Compound annual growth rate and
forecast till 2026
Peptide Receptor Radionuclide Therapy (PRRT) Market, by Disease Indication
(Gastroenteropancreatic Neuroendocrine Tumor, Foregut Neuroendocrine
Tumor, Midgut Neuroendocrine Tumor, and Hindgut Neuroendocrine Tumor) by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity
Analysis, 2019 – 2027
Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as
radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy a peptide similar to
the natural hormone is combined with radioactive material such as Yttrium and Lutetium, to produce
radionuclide which is then injected into the patient’s body. This combination binds to the
neuroendocrine tumors in the body. It is a cell targeting type of therapy since it delivers a high dose of
radiation directly to the tumor cells. Click To Read More On Peptide Receptor Radionuclide
Therapy (PRRT) Market.
Global Peptide Receptor Radionuclide Therapy (PRRT) Market Drivers
Increasing number of drug approvals by regulatory bodies is expected to drive the global peptide
receptor radionuclide therapy market growth over the forecast period. For instance, in January 2018,
Advanced Accelerator Applications S.A. received an approval from U.S. Food & Drug Administration
for Lutathera, a peptide receptor radionuclide therapy. It is used for treating gastroenteropancreatic
neuroendocrine tumors. Its phase 3 study showed 79% reduction in the disease progression. Moreover,
it is the only approved peptide receptor radionuclide therapy drug.
Furthermore, key players are also focused on research and development activities related to peptide
receptor radionuclide therapy which is expected to accelerate the global peptide receptor radionuclide
therapy market growth. For instance, in July 2017, National Institute of Health commenced its clinical
trial study on Y-DOTATOC. The drug is currently in the early phase of trials, and is being evaluated for
micro-dosing. It will be used for treating neuroendocrine tumors. Such development of drugs is
expected to boost the global peptide receptor radionuclide therapy market growth.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2731
Also, strategies such as mergers, acquisitions, partnerships, and collaborations by key players related to
peptide receptor radionuclide therapy are expected to propel the global peptide receptor radionuclide
therapy market growth over the forecast period. For instance, in January 2018, Novartis AG, a
biopharmaceutical company acquired Advanced Accelerator Applications S.A., a manufacturer of
nuclear medicine products, in order to expand Novartis AG’s product portfolio. This acquisition was for
the diversification of oncology neuroendocrine tumor treatment and addition of the
radiopharmaceutical technology platform to its portfolio. The growing number of acquisitions are
expected to fuel demand for the global peptide receptor radionuclide therapy market.
Global Peptide Receptor Radionuclide Therapy (PRRT) Market Regional Analysis
North America is expected to be a dominant region in the peptide receptor radionuclide therapy market.
Higher incidences of prostate cancer is expected to support the global peptide receptor radionuclide
therapy market growth. According to Center of Disease Control and Prevention’s data for 2016, around
192,443 people suffered from prostate cancer and almost 30,370 died due to it. Prostate cancer is
considered the fourth leading cause of death due to cancer. Hence, increasing prevalence of prostate
cancer is expected to augment the peptide receptor radionuclide therapy market growth during the
forecast period.
Global Peptide Receptor Radionuclide Therapy (PRRT) Market Taxonomy
The global peptide receptor radionuclide therapy (PRRT) market is segmented on the basis of disease
indications, distribution channels, and regions.
By Disease Indication
•Gastroenteropancreatic Neuroendocrine Tumor
•Foregut Neuroendocrine Tumor
•Midgut Neuroendocrine Tumor
•Hindgut Neuroendocrine Tumor
By Distribution Channel
•Hospital Pharmacies
•Retail Pharmacies
•Online Pharmacies
Global Peptide Receptor Radionuclide Therapy (PRRT) Market Key Players
Some of the major player operating in the global peptide receptor radionuclide therapy (PRRT) market
include, Novartis AG, ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal
Trials Group, Toulouse University Hospital, Peking University, and others.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran303   documents Email
Document
Category
Health and Medicine
Views
3
File Size
381 KB
Tags
receptor
1/--pages
Report inappropriate content